CGRP monoclonal antibodies: general aspects
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
CGRP monoclonal antibodies: general aspects. The CGRP mAbs are indicated for episodic or chronic migraine. Fully referenced neurology checklist.
Indications
- The CGRP mAbs are indicated for episodic or chronic migraine
- They provide sustained reductions in migraine headaches over 2 years
- They are usually indicated after the failure of ≥2 other prophylactic drugs
- They may be considered in migraine with medication overuse headache
- A recent guideline however recommends their use as first line prophylactic options
General contraindications
Locked: subscribe to see this section.
Administration
Locked: subscribe to see this section.
Precautions
Locked: subscribe to see this section.
General adverse effects
Locked: subscribe to see this section.
Management of non-responders
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Hou M, Xing H, Cai Y, et al. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain 2017; 18:42.
- Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta analysis. Clin Neurol Neurosurg 2017; 154: 74-78.
- Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol 2017; 30:272-280.
- Schuster NM, Rapoport AM. Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache: a review. Clin Neuropharmacol 2017; 40:169-174.
- Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol 2017; 30:272-280.
- And 6 more. Subscribe to see the full list
